Skip to main content
. 2023 Nov 10;9(11):e22178. doi: 10.1016/j.heliyon.2023.e22178

Table 1.

Baseline characteristics of patient population based on discharge day.

Overall
N = 1830
Same-day discharge group
N = 350 (19 %)
Overnight stay
N = 1480 (81 %)
P - value
Age in years 65.87 ± 9.9 63.62 ± 9.61 66.42 ± 9.9 <0.001
Male 1256 (69.7 %) 278 (78.1 %) 978 (67.7 %) <0.001
White Race 1558 (86.5 %) 317 (89 %) 1241 (85.9 %) 0.13
CAD 391 (21.7 %) 61 (17.4 %) 328 (22.2 %) 0.061
Cardiomyopathy 420 (22 %) 66 (18.9 %) 354 (23.9 %) 0.051
Ejection Fraction in % 55.47 ± 9.95 56.4 ± 8.75 55.23 ± 10 0.037
Non-paroxysmal AF 1052 (57.4 %) 188 (53.7 %) 864 (58.4 %) 0.127
CHA2DS2-VASc Score 2.49 ± 1.54 2.03 ± 1.41 2.73 ± 1.48 <0.001
Diabetes Mellitus 296 (16.2 %) 43 (12.3 %) 243 (16.4 %) 0.067
Dialysis 6 (0.3 %) 1 (0.3 %) 5 (0.3 %) 1
Hypertension 1143 (62.4 %) 197 (56.3 %) 946 (63.9 %) 0.01
History of CVA 139 (7.59 %) 29 (8.3 %) 110 (7.4 %) 0.66
COPD 89 (4.9 %) 13 (3.7 %) 76 (5.3 %) 0.22
PAD 52 (2.9 %) 9 (2.5 %) 43 (3 %) 0.78
Anticoagulant use 100 % 100 % 100 % NA
  • Apixaban

1181 (63.2 %) 219 (62.9 %) 915 (63.1 %) 0.74
  • Rivaroxaban

363 (20.5 %) 90 (25.9 %) 285 (19.7 %) 0.013
  • Dabigatran

32 (1.8 %) 7 (2 %) 24 (1.7 %) 0.68
  • Warfarin

185 (10.5 %) 25 (7.2 %) 163 (11.3 %) 0.03
Single Antiplatelet 529 (29 %) 70 (20 %) 466 (31.5 %) <0.001
DAPT 33 (2.7 %) 2 (0.6 %) 30 (2 %) 0.1
Beta-blocker 1244 (69.1 %) 237 (66.6 %) 1007 (69.7 %) 0.28
Antiarrhythmic use 902 (49.2 %) 154 (44 %) 748 (50 %) 0.02
  • Amiodarone

262 (29.6 %) 28 (18.2 %) 238 (31.8 %)
  • Dofetilide

282 (31.9 %) 54 (35.1 %) 234 (31.3 %)
  • Flecainidine

197 (22.3 %) 48 (31.2 %) 152 (20.3 %)
  • Sotalol

99 (11.2 %) 16 (10.4 %) 86 (11.5 %)
  • Propafenone

25 (2.8 %) 5 (3.2 %) 20 (2.7 %)
  • Others

20 (2.2) 3 (1.9 %) 18 (2.4 %)